Glycolipid Mimetics for TLR4 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory drugs, especially small molecule compounds, face challenges such as lack of target specificity and side effects, and there is a need for novel compounds that can effectively modulate the immune response by targeting the TLR4 receptor.
Innovation Solution
Development of metabolically stable glycolipid mimetics with a polysubstituted 2-oxa-3-oxoindolizidin-5-yl radical linked through an achiral pseudoamide functional group to a lipid aglycone, which can act as antagonists or agonists of the TLR4 receptor.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule anti-inflammatory drugs are used, then anti-inflammatory activity is achieved, but target specificity is lacking and side effects occur
Solution Approach 1:
The patent modifies the molecular structure of glycolipids by changing chemical parameters (substituents at positions 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40) to achieve high target specificity for TLR4 while reducing side effects. The specific modification of the glycolipid structure at multiple positions allows precise interaction with the TLR4 receptor.
Solution Approach 2:
The patent creates composite glycolipid molecules combining multiple functional groups and structural elements (carbohydrate moiety, lipid tail, and specific functional groups at various positions) to achieve both high target specificity for TLR4 and reduced side effects through the synergistic interaction of different molecular components.
2Reliability
If natural carbohydrate-based immunomodulators are used, then immune modulation activity is achieved, but sufficient quantity, purity and homogeneity are difficult to obtain
Solution Approach 1:
The patent creates synthetic copies of natural glycolipid structures with controlled molecular configurations. By replicating the active structural features of natural glycolipids through synthetic chemistry, the patent achieves sufficient quantity, purity, and homogeneity while maintaining immune modulation activity.
Solution Approach 2:
The patent modifies the physical and chemical parameters of glycolipid molecules (stereoselectivity, molecular weight, functional group positions) to optimize their immune modulation activity while ensuring sufficient quantity, purity, and homogeneity through controlled synthetic processes.
3Reliability
If glycolipid derivatives are synthesized with structural modifications, then anti-inflammatory activity is improved, but synthesis complexity increases
Solution Approach 1:
The patent divides the glycolipid molecule into distinct segments (carbohydrate moiety, lipid tail, functional groups at specific positions) and synthesizes each segment separately before assembling the complete structure. This segmentation approach reduces overall synthesis complexity while maintaining improved anti-inflammatory activity through precise structural control.
Data Source
AI summary
The invention relates to a 5-aminohexahydro-6,7,8-trihydroxy-3H-oxazo-lo[3,4-a]pyridin-3-one (i.e. 2,3,4-trihydroxy-5N,6O-oxomethylidene-nojirimycin-1-amine) glycol-ipid mimetic derivative of formula (I) acting as antagonists or agonist of the TLR4 for the treatment and/or prevention of an immune disease such as e.g. acute inflammation, chronic disease allergy, the Metabolic Syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), immune mediated hepatitis, an autoimmune disease, graft rejection pathology, inflammatory bowel disease, atherosclerosis and airway hyperactivity, such as e.g. asthma and allergic rhinitis. An exemplary compound is e.g. example 1, compound (1).